Pfizer Sues Novo Nordisk Over Alleged Tactics to Block Obesity Drug Competition 
United Airlines Tokyo-Bound Flight Returns to Dulles After Engine Failure 
Sanofi’s Efdoralprin Alfa Gains EMA Orphan Status for Rare Lung Disease 
Gold and Silver Surge as Safe Haven Demand Rises on U.S. Economic Uncertainty 
EU Signals Major Shift on 2035 Combustion Engine Ban Amid Auto Industry Pressure 
Novo Nordisk and Eli Lilly Lower Prices for Weight-Loss Drugs Amid U.S. Agreement 
LG Energy Solution Shares Slide After Ford Cancels EV Battery Supply Deal 
Cogent Biosciences Soars 120% on Breakthrough Phase 3 Results for Bezuclastinib in GIST Treatment 
Debate over H-1B visas shines spotlight on US tech worker shortages 
Pfizer Secures $10 Billion Deal for Obesity Drug Developer Metsera, Outbids Novo Nordisk 
Canada’s local food system faces major roadblocks without urgent policy changes 
Why a ‘rip-off’ degree might be worth the money after all – research study 
Asian Currencies Trade Sideways as Dollar Weakens Ahead of Key U.S. Data 
Youth are charting new freshwater futures by learning from the water on the water 
Dollar Struggles as Markets Eye Key Central Bank Decisions and Global Rate Outlooks 
U.S. Stock Futures Edge Higher as Micron Earnings Boost AI Sentiment Ahead of CPI Data 
Shell M&A Chief Exits After BP Takeover Proposal Rejected 
Bubs Australia will manufacture and distribute Bubs’ Chinese-label goat milk infant formula in China according to new Chinese standards. under an agreement with Heilongjiang Ubeite Dairy Group (HUG).
The new standards will come into effect in February 2023 .
The “ultra-premium” infant formula has been specially developed for Chinese infants using easily-digestible A2 goat-milk protein, sn2 palmitate (OPO), lactoferrin prebiotics, and nucleotides.
HUG has started submission with the State Administration for Market Regulation (SAMR) to renew its registration in line with China’s new GB standards for exclusive use under the Bubs brand.
According to Kristy Carr, Bubs founder and CEO, they have built strong brand trust and loyalty with Chinese families through marketing and selling Bubs English label infant formula products via the crossborder eCommerce channel, which accounts for around 20 percent of total Chinese infant formula sales.
If approved by SAMR, the formula will give Bubs access to the remaining 80 percent of China’s $25.9 billion infant formula market.
Bubs will also enter into a joint venture agreement, where it will hold a 75 percent interest, with Zhitong Health Technology to distribute its Chinese label goat infant formula products.
Bubs Australia expects to launch its product in the second half of FY23, subject to receiving SAMR approval.
